Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction
暂无分享,去创建一个
John Seibyl | Peter Bartenstein | Axel Rominger | Matthias Brendel | Andreas Delker | Marcus Högenauer | Julia Sauerbeck | J. Seibyl | A. Rominger | M. Brendel | J. Sauerbeck | Andreas Delker | P. Bartenstein | Marcus Högenauer
[1] C. Rowe,et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults , 2012, Neurology.
[2] Albert Gjedde,et al. Subcortical elevation of metabolism in Parkinson's disease — A critical reappraisal in the context of global mean normalization , 2009, NeuroImage.
[3] P. Pochet. A Quantitative Analysis , 2006 .
[4] Mark E. Schmidt,et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.
[5] Paul Edison,et al. Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans? , 2012, NeuroImage.
[6] Jochen Herms,et al. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [18F]-florbetaben PET , 2014, NeuroImage.
[7] N. Bohnen,et al. Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature , 2012, The Journal of Nuclear Medicine.
[8] Nick C Fox,et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.
[9] Keith A. Johnson,et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging , 2013, Alzheimer's & Dementia.
[10] L. Thurfjell,et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[11] Hellmuth Obrig,et al. Reference Cluster Normalization Improves Detection of Frontotemporal Lobar Degeneration by Means of FDG-PET , 2012, PloS one.
[12] C. Rowe,et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.
[13] Alexander Hammers,et al. Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18 , 2008, Psychiatry Research: Neuroimaging.
[14] Anders M. Dale,et al. Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data , 2006, NeuroImage.
[15] Rik Ossenkoppele,et al. Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations , 2013, The Journal of Nuclear Medicine.
[16] Arman Rahmim,et al. Design and Implementation of an Automated Partial Volume Correction in PET: Application to Dopamine Receptor Quantification in the Normal Human Striatum , 2008, Journal of Nuclear Medicine.
[17] Alexander Hammers,et al. Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.
[18] Kathryn Ziegler-Graham,et al. Worldwide variation in the doubling time of Alzheimer's disease incidence rates , 2008, Alzheimer's & Dementia.
[19] M. Chakravarty,et al. Brain Energy Metabolism and Blood Flow Differences in Healthy Aging , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] J. R.,et al. Quantitative analysis , 1892, Nature.
[21] Alan C. Evans,et al. A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.
[22] R. Boellaard,et al. Longitudinal amyloid imaging using [11]PIB: Choosing the right method , 2011 .
[23] I. Buvat,et al. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology , 2012, Physics in medicine and biology.
[24] M. Mintun,et al. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.
[25] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[26] R. Coleman,et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.
[27] Paul Maruff,et al. Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease , 2013, Alzheimer's & Dementia.
[28] Sung-Cheng Huang,et al. Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[29] A. Evans,et al. Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] C. Buchpiguel,et al. Age-Related Metabolic Profiles in Cognitively Healthy Elders: Results from a Voxel-Based [18F]Fluorodeoxyglucose–Positron-Emission Tomography Study with Partial Volume Effects Correction , 2011, American Journal of Neuroradiology.
[31] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[32] M. Modat,et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.